Apridex Capsule 40 mg contains Aprepitant, a selective neurokinin-1 (NK1) receptor antagonist used to prevent nausea and vomiting associated with chemotherapy and surgery. This medication is particularly effective in managing both acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV), providing patients with improved comfort and quality of life during cancer treatment.

Apridex works as part of a combination antiemetic regimen and is prescribed under medical supervision to enhance symptom control for patients undergoing highly or moderately emetogenic chemotherapy. Its oral capsule form allows convenient administration and accurate dosing.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

How It Works

Aprepitant, the active ingredient in Apridex Capsule, works by selectively blocking the neurokinin-1 (NK1) receptors in the central nervous system:

• Prevents Vomiting Signals: NK1 receptors bind to substance P, a neurotransmitter that triggers vomiting. By blocking these receptors, Aprepitant interrupts the vomiting reflex pathway.

• Controls Acute and Delayed Nausea: Effective against nausea occurring both immediately after chemotherapy and in delayed phases (24–120 hours post-therapy).

• Enhances Antiemetic Therapy: Often used in combination with 5-HT3 antagonists (e.g., ondansetron) and corticosteroids (e.g., dexamethasone) for comprehensive anti-nausea effects.

Through these mechanisms, Apridex ensures better management of chemotherapy-induced nausea, allowing patients to maintain nutrition, hydration, and overall well-being.

Indications

Apridex Capsule 40 mg is indicated for:

• Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in adults

• Use as part of a combination regimen with 5-HT3 receptor antagonists and corticosteroids

• Prevention of postoperative nausea and vomiting (PONV) in certain surgical procedures

This medication is intended for use under medical supervision and is not recommended for self-medication.

Dosage and Administration

• Recommended Dose: For prevention of CINV, the typical regimen includes a single 125 mg dose on day 1 (before chemotherapy), followed by 80 mg once daily on days 2 and 3. The 40 mg capsule may be used as part of divided or adjusted dosing schedules according to the physician’s discretion.

• Swallow the capsule whole with water; do not crush or chew.

• Take the medication at the prescribed times to maintain effective blood levels.

• Follow the complete antiemetic regimen recommended by your healthcare provider for optimal protection.

Benefits of Apridex Capsule

• Effectively prevents both acute and delayed chemotherapy-induced nausea and vomiting

• Enhances patient comfort and quality of life during cancer treatment

• Reduces the risk of dehydration and malnutrition due to vomiting

• Oral capsule allows convenient home or hospital use

• Can be combined with other antiemetics for comprehensive symptom control

Possible Side Effects

Most patients tolerate Apridex Capsule well. Common side effects may include:

• Fatigue or weakness

• Loss of appetite

• Diarrhea or constipation

• Headache

• Mild dizziness

Rare but serious side effects may include allergic reactions or severe liver enzyme abnormalities. Patients should contact their physician immediately if severe symptoms occur.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Use with caution in patients with liver impairment.

• Inform your doctor of all other medications to avoid interactions, especially chemotherapy or anticoagulants.

• Not recommended during pregnancy or breastfeeding unless specifically advised by a physician.

• Regular monitoring may be required in patients on long-term antiemetic therapy.

Storage Instructions

Store below 30°C in a cool, dry place away from light and moisture. Keep out of reach of children.

Apridex Capsule 40 mg (Aprepitant) is an effective, targeted therapy for preventing chemotherapy- and surgery-related nausea and vomiting, improving treatment tolerance and patient well-being under medical supervision.